Cannara Biotech Price To Sales Ratio Over Time

LOVE Stock  CAD 0.72  0.03  4.00%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cannara Biotech Performance and Cannara Biotech Correlation.
  
Price To Sales Ratio is likely to drop to 0.71 in 2024.
Please note, there is a significant difference between Cannara Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cannara Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cannara Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cross Equities Price To Sales Ratio Analysis

Compare Cannara Biotech and related stocks such as Decibel Cannabis, iShares Canadian HYBrid, and Altagas Cum Red Price To Sales Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
DB2.11382.11382.11382.11382.11382.11382.11382.11382.11382.11380.81311.01110.50950.45760.43
LOVE48948948948948948948948952.241726.56637.64233.30211.55960.74920.71
ERE-UN8.86158.86158.86158.86158.86158.86158.86158.861525.077510.85088.84449.42445.42541.65331.57

Cannara Biotech and related stocks such as Decibel Cannabis, iShares Canadian HYBrid, and Altagas Cum Red Price To Sales Ratio description

Price to Sales Ratio is figured by comparing Cannara Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cannara Biotech sales, a figure that is much harder to manipulate than other Cannara Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

My Equities

My Current Equities and Potential Positions

Cannara Biotech
LOVE
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address333 Decarie Blvd,
ExchangeTSX Venture Exchange
CAD 0.72

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.